TheraRadar
← Back
Data updated: Jun 28, 2026

IMMEDICA PHARMA AB

Biotech
Pharmaceuticals

IMMEDICA PHARMA AB is a biotechnology company with 1 FDA-approved products.

2026
Since
1
Drugs
-
Trials
1
New Drugs (2yr)

IMMEDICA PHARMA AB's Key Drugs

IMMEDICA PHARMA AB's core commercial portfolio centers on LOARGYS — its most strategically important drugs approved in the last 15 years.

LOARGYS
Oncology
Approved 2026

IMMEDICA PHARMA AB's Recent FDA Approvals

IMMEDICA PHARMA AB secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

LOARGYS BLA
2026-02-23
pegzilarginase-nbln
1 INDICATIONS AND USAGE LOARGYS is indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. This indication is approved under accelerated approval based on reduction of plasma arginine [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. LOARGYS is an arginine specific enzyme indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. ( 1 ) This indication is approved under accelerated approval based on reduction of plasma arginine. ( 14 ) Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 1 )

IMMEDICA PHARMA AB's Therapeutic Areas

Disease areas where IMMEDICA PHARMA AB has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

IMMEDICA PHARMA AB Pipeline Snapshot

Active clinical trials for IMMEDICA PHARMA AB across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Phase 3 Readout Calendar Pro

2 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q3 2028
Ganaxolone
CDKL5 Deficiency Disorder
Estimated · aging NCT05249556
Q1 2026
Chronocort
Congenital Adrenal Hyperplasia
Completed · awaiting NCT05299554

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • LOARGYS leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • 2 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling